Vertex Pharmaceuticals Acquires Crinetics in $10 Billion Deal at High Premium
Vertex Pharmaceuticals has acquired biotech firm Crinetics for approximately $10 billion, offering a significant premium of over 102% on its stock price. The deal is Vertex's largest acquisition to date and raises questions among investors about whether the company may have overpaid.